Santarus Inc., of San Diego, and Depomed Inc., of Menlo Park, Calif., inked a new commercialization deal for Glumetza (metformin hydrochloride extended-release tablets) under which Santarus will assume broad commercial, manufacturing and regulatory responsibilities to replace a promotion agreement signed in July 2008. The new terms call for Santarus to record revenue from Glumetza sales in the U.S., effective Sept. 1.